Human papillomavirus antibodies and future risk of anogenital cancer

A new study, led jointly by Mattias Johansson of the International Agency for Research on Cancer (IARC) and Aimée Kreimer of the United States National Cancer Institute, investigated the presence of human papillomavirus (HPV) antibodies in pre-diagnostic serum from 400 individuals diagnosed with anogenital cancer and 718 matched controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. HPV16 E6 seropositivity was found to be relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers. The report was published today in the Journal of Clinical Oncology

Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European Prospective Investigation into Cancer and Nutrition study
A. R. Kreimer, P. Brennan, K. A. Lang Kuhs, T. Waterboer, G. Clifford, S. Franceschi, et al.
J. Clin. Oncol. Published online 9 February 2015
Read article